vs

Side-by-side financial comparison of Natera, Inc. (NTRA) and Tempus AI, Inc. (TEM). Click either name above to swap in a different company.

Natera, Inc. is the larger business by last-quarter revenue ($665.5M vs $367.2M, roughly 1.8× Tempus AI, Inc.). Natera, Inc. runs the higher net margin — 7.1% vs -14.8%, a 21.9% gap on every dollar of revenue. On growth, Tempus AI, Inc. posted the faster year-over-year revenue change (83.0% vs 39.8%). Natera, Inc. produced more free cash flow last quarter ($37.8M vs $-41.5M). Over the past eight quarters, Tempus AI, Inc.'s revenue compounded faster (58.7% CAGR vs 34.5%).

Natera, Inc. is a clinical genetic testing company based in Austin, Texas that specializes in non-invasive, cell-free DNA (cfDNA) testing technology, with a focus on women’s health, cancer, and organ health. Natera’s proprietary technology combines novel molecular biology techniques with a suite of bioinformatics software that allows detection down to a single molecule in a tube of blood. Natera operates CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendment...

Tempus AI, Inc. is an American health technology company founded in 2015 by Eric Lefkofsky in Chicago, Illinois. It was established by Lefkofsky soon after his wife was diagnosed with breast cancer. Tempus uses data and artificial intelligence (AI) to create precision medicine services, including diagnostics, for oncology, cardiology, radiology, and depression. The company went public on the Nasdaq on June 14, 2024, under the ticker symbol "TEM."

NTRA vs TEM — Head-to-Head

Bigger by revenue
NTRA
NTRA
1.8× larger
NTRA
$665.5M
$367.2M
TEM
Growing faster (revenue YoY)
TEM
TEM
+43.2% gap
TEM
83.0%
39.8%
NTRA
Higher net margin
NTRA
NTRA
21.9% more per $
NTRA
7.1%
-14.8%
TEM
More free cash flow
NTRA
NTRA
$79.4M more FCF
NTRA
$37.8M
$-41.5M
TEM
Faster 2-yr revenue CAGR
TEM
TEM
Annualised
TEM
58.7%
34.5%
NTRA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
NTRA
NTRA
TEM
TEM
Revenue
$665.5M
$367.2M
Net Profit
$47.3M
$-54.2M
Gross Margin
Operating Margin
-3.4%
-16.7%
Net Margin
7.1%
-14.8%
Revenue YoY
39.8%
83.0%
Net Profit YoY
187.9%
-316.2%
EPS (diluted)
$0.36
$-0.30

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NTRA
NTRA
TEM
TEM
Q4 25
$665.5M
$367.2M
Q3 25
$592.2M
$334.2M
Q2 25
$546.6M
$314.6M
Q1 25
$501.8M
$255.7M
Q4 24
$476.1M
$200.7M
Q3 24
$439.8M
$180.9M
Q2 24
$413.4M
$166.0M
Q1 24
$367.7M
$145.8M
Net Profit
NTRA
NTRA
TEM
TEM
Q4 25
$47.3M
$-54.2M
Q3 25
$-87.5M
$-80.0M
Q2 25
$-100.9M
$-42.8M
Q1 25
$-66.9M
$-68.0M
Q4 24
$-53.8M
$-13.0M
Q3 24
$-31.6M
$-75.8M
Q2 24
$-37.5M
$-552.2M
Q1 24
$-67.6M
$-64.7M
Operating Margin
NTRA
NTRA
TEM
TEM
Q4 25
-3.4%
-16.7%
Q3 25
-16.5%
-18.3%
Q2 25
-20.2%
-19.6%
Q1 25
-15.8%
-26.9%
Q4 24
-13.6%
-25.3%
Q3 24
-8.9%
-29.6%
Q2 24
-10.6%
-321.4%
Q1 24
-20.2%
-36.5%
Net Margin
NTRA
NTRA
TEM
TEM
Q4 25
7.1%
-14.8%
Q3 25
-14.8%
-23.9%
Q2 25
-18.5%
-13.6%
Q1 25
-13.3%
-26.6%
Q4 24
-11.3%
-6.5%
Q3 24
-7.2%
-41.9%
Q2 24
-9.1%
-332.7%
Q1 24
-18.4%
-44.4%
EPS (diluted)
NTRA
NTRA
TEM
TEM
Q4 25
$0.36
$-0.30
Q3 25
$-0.64
$-0.46
Q2 25
$-0.74
$-0.25
Q1 25
$-0.50
$-0.40
Q4 24
$-0.41
$2.56
Q3 24
$-0.26
$-0.46
Q2 24
$-0.30
$-6.86
Q1 24
$-0.56
$-1.47

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NTRA
NTRA
TEM
TEM
Cash + ST InvestmentsLiquidity on hand
$604.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.7B
$491.3M
Total Assets
$2.4B
$2.3B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NTRA
NTRA
TEM
TEM
Q4 25
$604.8M
Q3 25
$1.0M
$655.9M
Q2 25
$16.0M
$186.3M
Q1 25
$17.8M
$151.6M
Q4 24
$22.7M
$341.0M
Q3 24
$29.5M
$388.0M
Q2 24
$90.3M
$478.8M
Q1 24
$69.1M
$79.9M
Stockholders' Equity
NTRA
NTRA
TEM
TEM
Q4 25
$1.7B
$491.3M
Q3 25
$1.3B
$507.8M
Q2 25
$1.2B
$309.6M
Q1 25
$1.2B
$326.2M
Q4 24
$1.2B
$56.3M
Q3 24
$878.5M
$53.7M
Q2 24
$836.5M
$98.3M
Q1 24
$794.1M
$-1.5B
Total Assets
NTRA
NTRA
TEM
TEM
Q4 25
$2.4B
$2.3B
Q3 25
$1.8B
$2.3B
Q2 25
$1.8B
$1.6B
Q1 25
$1.7B
$1.5B
Q4 24
$1.7B
$926.1M
Q3 24
$1.6B
$971.7M
Q2 24
$1.5B
$864.6M
Q1 24
$1.5B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NTRA
NTRA
TEM
TEM
Operating Cash FlowLast quarter
$73.9M
$-36.8M
Free Cash FlowOCF − Capex
$37.8M
$-41.5M
FCF MarginFCF / Revenue
5.7%
-11.3%
Capex IntensityCapex / Revenue
5.4%
1.3%
Cash ConversionOCF / Net Profit
1.56×
TTM Free Cash FlowTrailing 4 quarters
$109.1M
$-239.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NTRA
NTRA
TEM
TEM
Q4 25
$73.9M
$-36.8M
Q3 25
$59.4M
$-119.8M
Q2 25
$37.6M
$44.2M
Q1 25
$44.5M
$-105.6M
Q4 24
$52.9M
Q3 24
$51.8M
$48.7M
Q2 24
$4.0M
$-97.1M
Q1 24
$27.0M
$-101.4M
Free Cash Flow
NTRA
NTRA
TEM
TEM
Q4 25
$37.8M
$-41.5M
Q3 25
$37.0M
$-126.5M
Q2 25
$11.7M
$36.6M
Q1 25
$22.6M
$-107.7M
Q4 24
$34.8M
Q3 24
$35.5M
$48.6M
Q2 24
$-7.7M
$-105.1M
Q1 24
$6.7M
$-107.5M
FCF Margin
NTRA
NTRA
TEM
TEM
Q4 25
5.7%
-11.3%
Q3 25
6.2%
-37.9%
Q2 25
2.1%
11.6%
Q1 25
4.5%
-42.1%
Q4 24
7.3%
Q3 24
8.1%
26.9%
Q2 24
-1.9%
-63.3%
Q1 24
1.8%
-73.7%
Capex Intensity
NTRA
NTRA
TEM
TEM
Q4 25
5.4%
1.3%
Q3 25
3.8%
2.0%
Q2 25
4.7%
2.4%
Q1 25
4.3%
0.8%
Q4 24
3.8%
Q3 24
3.7%
0.0%
Q2 24
2.8%
4.8%
Q1 24
5.5%
4.2%
Cash Conversion
NTRA
NTRA
TEM
TEM
Q4 25
1.56×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons